As recently reported, a preponderant CD8+ T response is associated with mild COVID‐19 infection.[108] This advantage has led to great interest in VLP‐based vaccines for the treatment of cancer and chronic diseases.[109, 110, 111, 112, 113] The effective stimulation of a CD8+ T cell response and generation of CD8+ memory cells is now also deemed a vital perspective of vaccine development for infectious diseases.[114] Though it is well‐established that antigens presented by VLPs are prone to cross‐presentation,[115] the underlying mechanism remains to be fully elucidated. This evidence concerns the gene CD8A and cancer.